- Home
- TVTX
as 03-28-2025 4:00pm EST
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.9B | IPO Year: | N/A |
| Target Price: | $33.17 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.12 - $25.29 | Next Earning Date: | 05-05-2025 |
| Revenue: | $233,175,000 | Revenue Growth: | 60.55% |
| Revenue Growth (this year): | 72.95% | Revenue Growth (next year): | 53.84% |
Stock Insider Trading Activity of Travere Therapeutics Inc. (TVTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dube Eric M | TVTX | CHIEF EXECUTIVE OFFICER | Feb 11 '25 | Sell | $24.04 | 11,375 | $273,455.00 | 419,173 | |
| Calvin Sandra | TVTX | SVP, CHIEF ACCOUNTING OFFICER | Feb 11 '25 | Sell | $25.00 | 54,244 | $1,356,100.00 | 54,410 | |
| ROTE WILLIAM E. | TVTX | SENIOR VICE PRESIDENT, R&D | Feb 10 '25 | Sell | $23.53 | 5,200 | $122,356.00 | 98,519 | |
| REED ELIZABETH E | TVTX | SVP, GC & CORPORATE SECRETARY | Feb 10 '25 | Sell | $23.53 | 8,000 | $188,240.00 | 89,482 | |
| Heerma Peter | TVTX | CHIEF COMMERCIAL OFFICER | Feb 10 '25 | Sell | $24.27 | 5,642 | $137,275.55 | 127,634 | |
| Inrig Jula | TVTX | CHIEF MEDICAL OFFICER | Feb 10 '25 | Sell | $23.53 | 2,568 | $60,425.55 | 89,602 | |
| Baynes Roy D. | TVTX | Director | Feb 6 '25 | Sell | $22.00 | 10,000 | $220,000.00 | 31,000 | |
| Dube Eric M | TVTX | CHIEF EXECUTIVE OFFICER | Jan 31 '25 | Sell | $20.21 | 50,691 | $1,024,343.45 | 419,173 | |
| ROTE WILLIAM E. | TVTX | SENIOR VICE PRESIDENT, R&D | Jan 31 '25 | Sell | $19.78 | 8,951 | $177,050.78 | 98,519 | |
| Calvin Sandra | TVTX | SVP, CHIEF ACCOUNTING OFFICER | Jan 31 '25 | Sell | $20.12 | 3,348 | $67,361.76 | 54,410 |
Latest Travere Therapeutics Inc. News
TVTX Breaking Stock News: Dive into TVTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
Simply Wall St.
15 days ago
High Growth Tech Stocks In The US With Promising Potential
GlobeNewswire
17 days ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
Travere Therapeutics to Participate at Upcoming Investor Conferences
TipRanks
a month ago
Travere Therapeutics price target raised to $30 from $24 at TD Cowen
Simply Wall St.
a month ago
Travere Therapeutics Full Year 2024 Earnings: EPS Misses Expectations
GlobeNewswire
a month ago
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
GuruFocus.com
a month ago
What To Expect From Travere Therapeutics Inc (TVTX) Q4 2024 Earnings
Compare TVTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TVTX Travere Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.